Data: 25,26 e 27 de Junho de 2024
Formato: 100% Online
Apresentação:
• O Congresso Anual da Sociedade Americana de Oncologia Clínica (ASCO) traz inúmeras novidades com impacto direto na prática da oncologia. O objetivo desse evento é discutir os principais resultados apresentados em cada área, e trazê-los para o dia a dia do cuidado oncológico.
Público Alvo:
• Oncologistas clínicos, cirurgiões, rádio-oncologistas e médicos residentes.
Objetivo:
• Revisitar os principais trabalhos apresentados no Congresso Anual da ASCO, buscando traduzir e contextualizar seu significado, sempre de forma crítica e com discussões envolvendo nossas lideranças em oncologia.
Diferenciais:
• Exploração das novidades, revisão e uma contextualização das novas descobertas apresentadas no Congresso Anual da Sociedade Americana de Oncologia Clínica (ASCO), que é um dos mais importantes do mundo na área de oncologia.
Dra. Alessandra Salgues
Dra. Andrea Shimada
Dr. Artur Katz
Dr. Carlos dos Anjos
Dra. Caroline Chaul
Dr. Daniel Girard
Dra. Daniele Assad
Dr. David Muniz
Dr. Diogo Bastos
Dr. Felipe Canedo
Dra. Fernanda Caparelli
Dra. Fernanda Cesar Moura
Dr. Fernando Sabino
Dr. Frederico Perego Costa
Dr. Gilberto de Castro Junior
Dr. Guilherme Harada
Dr. João Alessi
Dra. Luiza Dib
Dra. Marina Sahade
Dr. Olavo Feher
Dr. Rodrigo Medeiros
Dr. Rodrigo Munhoz
Dr. Rudinei Linck
Dra. Tatiana Strava
Dr. Tulio Pfiffer
| Programação: Terça-feira, 25 de junho de 2024
*Programação sujeita a alterações e confirmações de convidados |
|
| 17:30 – 17:40 |
Abertura Dr. Artur Katz |
| 17:40 - 18:10 | Simpósio Satélite Daiichi-Sankyo Novas perspectivas para o tratamento de pacientes HER2 Dra. Andrea Shimada e Dra. Daniele Assad |
|
Módulo: Mama Coordenador: Dr. Artur Katz |
|
| 18:10 - 18:30 |
Trabalhos selecionados – Parte 1 Dra. Marina Sahade Doença inicial - LBA 500 - A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. - Abstract 1010 - Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. - Abstract 511 - Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline. - Abstract 513 - The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer. |
| 18:30 - 18:50 |
Trabalhos selecionados – Parte 2 Dra. Andrea Shimada Doença avançada - LBA 1001 - Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. - LBA 1000 - Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). - Abstract 1003 - First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑ negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses. - Abstract 104 - Tinha entendido que no local do TROPION-Breast 01 iriamos de Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. |
| 18:50 - 19:10 |
Resultados em perspectiva Dr. Carlos dos Anjos |
| 19:10 - 19:30 |
Discussão e Q&A – mama Debatedores: Dr. Artur Katz, Dra. Marina Sahade, Dra. Andrea Shimada e Dr. Carlos dos Anjos |
|
Módulo: Tumores ginecológicos Coordenadora: Dra. Daniele Assad |
|
| 19:30 - 19:50 |
Trabalhos selecionados – Parte 1 Dra. Fernanda Moura - Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial. -Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A final overall survival analysis of a multicenter, open-label, randomized, phase 3 -Atezolizumab versus placebo in combination with bevacizumab and nonplatinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOTov34 study. -Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extrarenal clear cell carcinomas |
| 19:50 - 20:10 |
Trabalhos selecionados – Parte 2 Dr. Rudinei Linck -Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study. -Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724. -Long-term survival outcomes for hormonal therapy in premenopausal patients with clinical stage I endometrial cancer. -Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study |
| 20:10 - 20:30 |
Resultados em perspectiva Dra. Daniele Assad |
| 20:30 - 20:50 |
Discussão e Q&A – Tumores ginecológicos Debatedores: Dra. Daniele Assad, Dra. Fernanda Moura e Dr. Rudinei Linck |
| 20:50 | Encerramento do primeiro dia |
| Programação: Quarta-feira, 26 de junho de 2024
*Programação sujeita a alterações e confirmações de convidados |
|
| 18:00 - 18:10 |
Abertura Dr. Artur Katz |
|
Módulo: Melanoma/Sarcoma Coordenador: Dr. Rodrigo Munhoz |
|
| 18:10 - 18:30 |
Trabalhos selecionados – Parte 1 Dra. Alessandra Salgues - Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. - Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN). - Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A. |
| 18:30 - 18:50 |
Trabalhos selecionados – Parte 2 Dra. Tatiana Strava - Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. - Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. - Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial. |
| 18:50 - 19:10 |
Resultados em perspectiva Dr. Rodrigo Munhoz |
| 19:10 - 19:30 |
Discussão e Q&A – Melanoma/Sarcoma Debatedores: Dr. Rodrigo Munhoz, Dra. Alessandra Salgues e Dra. Tatiana Strava |
|
Módulo: Tumores GU Coordenador: Dr. Diogo Bastos |
|
| 19:30 - 19:50 |
Trabalhos selecionados – Parte 1 Dr. David Muniz - Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy. - Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOGACRIN Cancer Research Group (EA8153). - Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore. |
| 19:50 - 20:10 |
Trabalhos selecionados – Parte 2 Dr. Fernando Sabino - Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer. - Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. - A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial. |
| 20:10 - 20:30 |
Resultados em perspectiva Dr. Daniel Girardi |
| 20:30 - 20:50 |
Discussão e Q&A – GU Debatedores: Dr. Diogo Bastos, Dr. David Muniz, Dr. Fernando Sabino e Dr. Daniel Girardi |
| 20:50 | Encerramento do segundo dia |
| Programação: Quinta-feira, 27 de junho de 2024
*Programação sujeita a alterações e confirmações de convidados |
|
| 17:30 - 17:40 |
Abertura Dr. Artur Katz |
| 17:40 - 18:10 |
Simpósio Satélite Roche Imunoterapia na Adjuvância | Updates ASCO IMpower010 Dr. Ricardo Dahmer |
|
Módulo: Pulmão e Cabeça/Pescoço Coordenador: Dr. Gilberto de Castro Junior |
|
| 18:10 - 18:30 |
Trabalhos selecionados – Parte 1 Dr. João Alessi - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. - Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study - Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). |
| 18:30 - 18:50 |
Trabalhos selecionados – Parte 2 Dr. Guilherme Harada - A randomized, double-blind placebo-controlled study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancer at high risk of recurrence: the PATHWay Study. - Tisotumab vedotin in head and neck squamous cell carcinoma: update analysis from innovaTV207 Part C - Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): a trial of the ECOG-ACRIN Cancer Research Group. |
| 18:50 - 19:10 |
Resultados em perspectiva Dr. Rodrigo Medeiros |
| 19:10 - 19:30 |
Discussão e Q&A – Pulmão e Cabeça/Pescoço Debatedores: Dr. Gilberto de Castro Junior, Dr. João Alessi, Dr. Guilherme Harada e Dr. Rodrigo Medeiros |
|
Módulo: Tumores GI Coordenador: Dr. Frederico Costa |
|
| 19:30 - 19:50 |
Trabalhos selecionados – Parte 1 Dra. Luiza Dib - Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial" (ASCO Conferences). - A phase 3, randomized study of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma: CheckMate 9DW" (Cancer Network). - A randomized trial comparing perioperative chemotherapy with FLOT versus perioperative chemotherapy with FOLFOX followed by surgery in patients with resectable esophageal or gastroesophageal junction adenocarcinoma: The ESOPEC trial" (Cancer Network). |
| 19:50 - 20:10 |
Trabalhos selecionados – Parte 2 Dr. Tulio Pfiffer - Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases - Surgery versus thermal ablation for small-size colorectal liver metastases - Durable complete responses to PD-1 blockade alone in dMMR locally advanced rectal cancer (Dostarlimab) |
| 20:10 - 20:30 |
Resultados em perspectiva Dra. Fernanda Caparelli |
| 20:30 - 20:50 |
Discussão e Q&A – GI Debatedores: Dr. Frederico Costa, Dra. Luiza Dib, Dr. Tulio Pfiffer e Dra. Fernanda Caparelli |
|
Módulo: Neuro Coordenador: Dr. Olavo Feher |
|
| 20:50 - 21:10 |
Trabalhos selecionados – Parte 1 Dr. Felipe Canedo - Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. - A Phase 2 Study of Tovorafenib in Pediatric Patients with Relapsed or Progressive Low-Grade Glioma. - A Phase 2 Study of Abemaciclib in Patients with Recurrent or Progressive Meningiomas. - A Phase 1/2 Study of CAR T-cells Targeting CD19 for Patients with Primary Central Nervous System Lymphoma (PCNSL). |
| 21:10 - 21:30 |
Resultados em perspectiva Dra. Carolina Chaul |
| 21:30 - 21:40 |
Discussão e Q&A – Neuro Debatedores: Dr. Olavo Feher, Dr. Felipe Canedo e Dra. Carolina Chaul |
| 20:50 | Encerramento do último dia |
